Simulations Plus, Inc. · NASDAQ:SLP

Simulations Plus — Merger or Acquisition (July 2014)

9 slides from Simulations Plus's merger presentation, Jul 29, 2014

  1. Slide 1: Simulations Plus, Inc. Cognigen Acquisition Conference Call/Webinar

    Simulations Plus, Inc. (NASDAQ:SLP) Cognigen Acquisition Conference Call/Webinar July 25, 2014 simulationsplus, inc, ¢

  2. Slide 2: Safe Harbor Statement

    With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to su

  3. Slide 3: Ted Grasela, President and CEO, Cognigen Corporation

    Cognigen Ted Grasela, PharmD, PhD President and CEO, Cognigen Corporation

  4. Slide 4: Cognigen: Incorporated in 1992

    Cognigen * Incorporated in 1992 in Buffalo NY ° First contract research organization to offer modeling services to Pharma ° Three partners ¢ Ted Grasela, President and CEO * Cindy Walawander, EVP and COO ¢ Jill Fiedler-Kelly, VP, Pharmacometric Services and Chief Science Officer * 35 employees: 1/3

  5. Slide 5: Modeling and Simulation Services

    Cognigen ‘simulations Modeling and Simulation Services plus. inc. * Critical path projects delivering mechanistic understanding of disease biology and drug pharmacology at decision milestones * Key role in clinical program design and GO/ NO GO decisions ° Selecting and justifying = dose for regulato

  6. Slide 6: Significant investment in IT infrastructure and workflow processes

    Cognigen * Significant investment in IT infrastructure and workflow processes ¢ Recently upgraded computer systems, implemented automated offsite backup storage, and installed green technology to reduce computer cooling costs ° Fully validated, “private” cloud computing to address computational requ

  7. Slide 7: Why the Merger?

    ©2014 Cognigen Corporation • Simulations Plus has the talent and experience to translate science into software • Cognigen see the “surprises” in clinical R&D - the unexpected findings that provide new insights into disease biology and drug pharmacology • Opportunity to turn our insights and work pro

  8. Slide 8: Thank you.

    ©2014 Cognigen Corporation Thank you. 8

  9. Slide 9: simulationsplus, ine, g

    simulationsplus, ine, g

Simulations Plus — Merger or Acquisition (July 2014) on 6ix